Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$432.72 0.73 (0.17)%
Market Cap 45.17B
09/22/17 4:00 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Important Note Regarding the September 11, 2017 Press Release Announcing Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent AsthmaRead on
Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic DermatitisRead on
Sep 16, 2017
Bank of America Merrill Lynch Global Healthcare Conference
Sep 13, 2017 | 5:40 AM ET